CTLA4 and neoplasm: Further, in the case of poorly immunogenic tumors, which have a limited endogenous immune response, the combination of CTLA-4 antibody with a vaccine has the potential to establish an immune response to hinder tumor growth and lead to tumor regression in certain cases[2, 28].